Teleflex Incorporated Company Overview NYSE: TFX

Transcription

1 Teleflex Incorporated Company Overview NYSE: TFX

2 Forward Looking Statements 2 This presentation and our discussion contain forward-looking information and statements including, but not limited to, our ability to improve our gross margin by 250 bps to 350 bps over a multi-year period through reduction of our facility footprint and relocation to low-cost locations, reductions in direct material spending and improvements to packaging, investment in automation and other initiatives; the potential application of our Cuff Pilot technology to our LMA laryngeal masks; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward looking statements. These risks and uncertainties are addressed in the Company s SEC filings, including its most recent Form 10-K. The following slides reflect continuing operations.

3 Teleflex at a Glance 3 Global provider of medical devices with leading market positions Annual Revenues: $1.7 billion (2013) Serving healthcare providers in more than 150 countries Employees: 11,000+ organized into regions, divisions and global functions Established global sales and distribution network Well known brands in vascular and interventional access, anesthesia, respiratory, urology, cardiac care and surgery

4 Our Story 4 Historically a diversified company, Teleflex has transformed its portfolio to become a pure play medical device company Began as a specialty engineering company 70 years ago More than 35 years in medical device industry Acquired established brands over time Established global medical device sales channels Strategic business unit structure: International (EMEA and Asia), Latin America, Anesthesia/Respiratory, Cardiac Care, OEM, Specialty, Surgical and Vascular Access

5 Our Products 5 Vascular Access Surgical Specialty Cardiac Care Anesthesia / Respiratory OEM Central, Peripheral and Arterial Vascular Access Catheters Catheter Tip Positioning Systems Intraosseous access devices Sheath Introducers Ligation Systems Closure Devices Laparoscopic Access Ports/Trocars General & Specialty Instruments Chest Drainage Systems Foley Catheters Intermittent Catheters Atomization Dialysis Catheters PTA Balloons Interventional Access Intra Aortic Balloon Pumps IAB Catheters TransRadial Access Right Heart Products Percutaneous Sheath Introducers Supraglottic Airways Atomization Epidurals Peripheral Nerve Blocks Airway Management Respiratory Therapy Specialty Sutures Catheter Fabrication Performance Fibers Custom Engineered Precision Extrusion Vascular Access Accessories CV Sutures ~ $390 million ~ $307 million ~ $248 million ~ $76 million ~ $544 million ~ $131 million Note: Figures represent 2013 revenues per Form 10K.

6 Our Markets 6 12% 53% 9% 7% 84% 35% Americas Europe, Middle East, Africa Asia Hospitals and Healthcare Providers Medical Device Manufacturers Home Health 2013 Revenue: $1.7 Billion Note: Amounts shown represent percentages of total revenues for the twelve months ended December 31, 2013, per Form 10K.

7 Key Elements of our Strategic Growth Plan 7 Pricing close the gap between ourselves and competitors; 2014 focused on distributor-to-direct conversions Innovation new product introductions and line extensions Rationalization reduce facility footprint Investments key geographic, capital and R&D initiatives Acquisitions build the portfolio Service value proposition

8 Focus on Innovation: Key New Product Launches 8 Softech Plus Nasal Cannula Use: oxygen delivery Weck AE5 Use: automatic endo applier Weck Efx Use: Closure system Arrow FlexBlock Continuous Peripheral Nerve Block Catheter 4,5,6Fr IR PICC Use: peripheral inserted catheter for smooth insertion EZ Blocker Use: lung isolation and ventilation IR PICC w/ Chloragard Use: central venous catheter Hotspur GPS Cath Use: treatment of obstructive lesions 2012 Trans-Radial Use: artery cardiac catheter Arrow FlexTip Plus Multi-Port Epidural Catheter Pre-loaded PICC w/ ARROW VPS Use: replaces need for X-ray CE Mark Chronic Hemodialysis Use: dialysis access Weck Vista Balloon Expansion Use: entry into the preitoneum (abdomen) AT 510(k) on PICC Use: catheter with Chlorhexidine solution Weck Vista Optical Trocar Use: clear visualization of tissue layers ISO-Gard Circuit Technology Use: circuit condensation management CE Mark PICC & VPS Use: avoid thrombosis, arterial puncture and vessel wall damage Weck Vista Reposable Obturator Use: controlled entry Anesthesia/Respiratory Vascular Access Surgical International

9 Margin Improvement Initiatives 9 Though no plans approved to date, we are evaluating opportunities to: Reduce facility footprint and relocate manufacturing capacity to low-cost locations Reduce direct material spending and make improvements to packaging Invest in automation and become less reliant on manual labor Through these and other initiatives, we believe there is an opportunity to improve gross margin by 250bps to 350bps over a multi-year period

10 Acquisition Approach 10 Fits into our existing strategic business unit franchises and call points Product provides a superior clinical benefit to existing alternatives Provides a cost benefit to a hospital Strong IP and patent protection Difficult for competitors to follow

11 ARROW VPS 11 Adoption of ARROW VPS in U.S. market continues CE Mark certification received on VPS International product release in Q1 2013

12 Semprus Biosciences (Sustain technology design) 12 Proteins, RBCs & Bacteria Protective Water Layer Semprus Sustain Polymer Medical Device Surface Semprus Sustain Technology Approximately 1 µm (1/100 th the Width of a Human Hair) Human Hair (~100 µm)

13 Hotspur Technologies 13

14 Weck EFx Endo Fascial Closure System 14 Endo Fascial Closure System designed for: Reproducible, uniform closure across patient anatomy Minimized risk of needle-stick injury Facilitates unassisted technique More than 750 clinical cases have been performed with the device in the United States 2012 Innovation of the Year -

15 EZ-Blocker TM 15 Acquired single-use catheter product line during 2nd quarter of 2012 Patented bronchial blocker for lung isolation and one-lung ventilation Addition to Rusch Airway portfolio Unique bifurcated distal end CE Mark approval obtained in Europe 510(k) approval September 2012

16 LMA International N.V. and affiliates 16 Global market leader in laryngeal masks Provides access to key clinical U.S. and international call points and further strengthens Group Purchasing Organization relationships Multi-year integration of LMA acquisition ahead of schedule Continued market adoption of second generation device in all regions

17 Ultimate Medical 17 A leading supplier and innovator of airway management devices, including a full-range of laryngeal mask airways Developed the Cuff Pilot TM, the world's first integrated cuff pressure indicator for airway management devices. This novel technology allows clinicians to continuously assess cuff pressure which may reduce the risk of aspiration and tracheal injury. Cuff Pilot TM technology is currently used with Ultimate Medical s portfolio of laryngeal masks and has potential application for use with LMA TM laryngeal masks

18 Eon Surgical 18 Acquired in June of 2013, Eon Surgical is a late stage development company that has advanced a minimally invasive micro-laparoscopy surgical platform technology designed to enhance surgeons ability to perform scarless surgery while producing better patient outcomes Developed the InterTip platform, a complete solution for performing scarless laparoscopic surgery, that unlike single-port laparoscopy allows the surgeon to maintain the triangulation of standard laparoscopic surgery Tools Intersleeve Camera Telescoping Needle with Handle

19 Vidacare Corporation 19 Company Overview Established in 2001, Vidacare Corporation is the developer of a broad technology platform that is defining the field of intraosseous (inside the bone access) medicine Focus on enhancing clinical efficacy, patient safety and comfort, and reducing complications and their associated costs Strategic Fit Expands vascular access product portfolio with a defining technology and moves TFX into the IO segment Strengthen EMS channel & Nursing call points High gross and operating margin profile Product Unique platform technology for immediate vascular access and bone marrow biopsy based driver system Razor/Razor blade model (Driver and Needle) Patented technology with strong brand equity

20 Mayo Healthcare Pty. Ltd. 20 Acquisition of one of Australia s largest medical device distributors completed in February 2014 Provides high quality products, education services, technical services and customer support to healthcare institutions throughout Australia Accretive, all-cash transaction

21 Service 21 We want to be the partner of choice for all customers Significant improvement made during last two years 1. On-time deliveries to customers 2. Reduction of backorders Well-positioned with all major Group Purchasing Organizations and Integrated Delivery Networks

22 Summary 22 Well-positioned portfolio of products able to take advantage of shifting healthcare environment Success in the future not dependent upon continued generation of above-market revenue growth Opportunity to improve operating leverage over multi-year period Opportunistic and conservative approach to future M&A Committed to the achievement of longer-term financial goals

23 Thank You